Immunogenicity of Different Types of Adjuvants and Nano-Adjuvants in Veterinary Vaccines: A Comprehensive Review

Overview

Journal Vaccines (Basel)

Date 2023 Feb 28

PMID 36851331

Authors

Soren Nooraei

Alireza Sarkar Lotfabadi

Milad Akbarzadehmoallemkolaei

Nima Rezaei

Affiliations

Soon will be listed here.

Abstract

Vaccination is the best way to prevent and reduce the damage caused by infectious diseases in animals and humans. So, several vaccines are used for prophylactic purposes before the pathogen infects, while therapeutic vaccines strengthen the immune system after infection with the pathogen. Adjuvants are molecules, compounds, or macromolecules that enhance non-specific immunity and, in collaboration with antigen(s), can improve the body's immune responses and change the type of immune response. The potential and toxicity of adjuvants must be balanced to provide the safest stimulation with the fewest side effects. In order to overcome the limitations of adjuvants and the effective and controlled delivery of antigens, attention has been drawn to nano-carriers that can be a promising platform for better presenting and stimulating the immune system. Some studies show that nanoparticles have a more remarkable ability to act as adjuvants than microparticles. Because nano-adjuvants inactively target antigen-presenting cells (APCs) and change their chemical surface, nanoparticles also perform better in targeted antigen delivery because they cross biological barriers more easily. We collected and reviewed various types of nano-adjuvants with their specific roles in immunogenicity as a prominent strategy used in veterinary vaccines in this paper.

Citing Articles

Advancing veterinary vaccines design through trained immunity insights.

Wang X, Yu G Front Vet Sci. 2025; 11:1524668.

PMID: 39881716 PMC: 11776093. DOI: 10.3389/fvets.2024.1524668.

Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model.

Mirzaei Z, Sari S, Moghaddam Pour M, Hassanzadeh S, Damizadeh B, Taghizadeh M Iran J Basic Med Sci. 2025; 28(2):224-229.

PMID: 39850119 PMC: 11756728. DOI: 10.22038/ijbms.2024.81654.17671.

Recent Advances in Oral Vaccines for Animals.

Zhong K, Chen X, Zhang J, Jiang X, Zhang J, Huang M Vet Sci. 2024; 11(8).

PMID: 39195807 PMC: 11360704. DOI: 10.3390/vetsci11080353.

Layered Double Hydroxides (LDH) as Delivery Vehicles of a Chimeric Protein Carrying Epitopes from the Porcine Reproductive and Respiratory Syndrome Virus.

Alonso-Cerda M, Garcia-Soto M, Miranda-Lopez A, Segura-Velazquez R, Sanchez-Betancourt J, Gonzalez-Ortega O Pharmaceutics. 2024; 16(7).

PMID: 39065539 PMC: 11279870. DOI: 10.3390/pharmaceutics16070841.

Immunostimulatory Effect of Ovomucin Hydrolysates by Pancreatin in RAW 264.7 Macrophages via Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway.

Jang J, Lee J, Kim K, Ahn D, Paik H Food Sci Anim Resour. 2024; 44(4):885-898.

PMID: 38974730 PMC: 11222692. DOI: 10.5851/kosfa.2024.e25.

References

Joffre O, Segura E, Savina A, Amigorena S . Cross-presentation by dendritic cells. Nat Rev Immunol. 2012; 12(8):557-69. DOI: 10.1038/nri3254. View

Fleck J, Betti A, da Silva F, Troian E, Olivaro C, Ferreira F . Saponins from and : Particular Chemical Characteristics and Biological Activities. Molecules. 2019; 24(1). PMC: 6337100. DOI: 10.3390/molecules24010171. View

Gupta R, RELYVELD E, Lindblad E, Bizzini B, Ben-Efraim S, Gupta C . Adjuvants--a balance between toxicity and adjuvanticity. Vaccine. 1993; 11(3):293-306. DOI: 10.1016/0264-410x(93)90190-9. View

Gregory A, Titball R, Williamson D . Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013; 3:13. PMC: 3607064. DOI: 10.3389/fcimb.2013.00013. View

Mottram P, Leong D, Crimeen-Irwin B, Gloster S, Xiang S, Meanger J . Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm. 2007; 4(1):73-84. DOI: 10.1021/mp060096p. View

Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A . Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines. 2011; 10(7):1053-61. DOI: 10.1586/erv.11.48. View

Jeevanandam J, Barhoum A, Chan Y, Dufresne A, Danquah M . Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018; 9:1050-1074. PMC: 5905289. DOI: 10.3762/bjnano.9.98. View

Cappellano G, Abreu H, Casale C, Dianzani U, Chiocchetti A . Nano-Microparticle Platforms in Developing Next-Generation Vaccines. Vaccines (Basel). 2021; 9(6). PMC: 8228777. DOI: 10.3390/vaccines9060606. View

Silva A, Soema P, Slutter B, Ossendorp F, Jiskoot W . PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccin Immunother. 2016; 12(4):1056-69. PMC: 4962933. DOI: 10.1080/21645515.2015.1117714. View

10.

Sinha V, Singh A, Kumar R, Singh S, Kumria R, Bhinge J . Oral colon-specific drug delivery of protein and peptide drugs. Crit Rev Ther Drug Carrier Syst. 2007; 24(1):63-92. DOI: 10.1615/critrevtherdrugcarriersyst.v24.i1.30. View

11.

Heegaard P, Dedieu L, Johnson N, Le Potier M, Mockey M, Mutinelli F . Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Arch Virol. 2010; 156(2):183-202. DOI: 10.1007/s00705-010-0863-1. View

12.

Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C . Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A. 2008; 105(30):10501-6. PMC: 2483233. DOI: 10.1073/pnas.0804699105. View

13.

Ways T, Lau W, Khutoryanskiy V . Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers (Basel). 2019; 10(3). PMC: 6414903. DOI: 10.3390/polym10030267. View

14.

Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila Jato J . Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm. 2004; 57(1):123-31. DOI: 10.1016/j.ejpb.2003.09.006. View

15.

Meeusen E, Walker J, Peters A, Pastoret P, Jungersen G . Current status of veterinary vaccines. Clin Microbiol Rev. 2007; 20(3):489-510, table of contents. PMC: 1932753. DOI: 10.1128/CMR.00005-07. View

16.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

17.

Rappuoli R, Mandl C, Black S, De Gregorio E . Vaccines for the twenty-first century society. Nat Rev Immunol. 2011; 11(12):865-72. PMC: 7098427. DOI: 10.1038/nri3085. View

18.

Amigorena S, Savina A . Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol. 2010; 22(1):109-17. DOI: 10.1016/j.coi.2010.01.022. View

19.

de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies A . Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013; 110(49):19902-7. PMC: 3856841. DOI: 10.1073/pnas.1313152110. View

20.

Golan-Paz S, Frizzell H, Woodrow K . Cross-Platform Comparison of Therapeutic Delivery from Multilamellar Lipid-Coated Polymer Nanoparticles. Macromol Biosci. 2018; 19(4):e1800362. PMC: 6467716. DOI: 10.1002/mabi.201800362. View